Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets

LIPELLA PHARMACEUTICALS INC.

Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
Non-compliance with Listing Rules 5635(d) and 5640 due to Series C preferred and warrants issued in Dec 2024-Mar 2025 private placements.
Common stock now quoted on OTC Markets under symbol LIPO; company exploring other listing venues.
Company disappointed, states business fundamentals intact; continuing clinical development of LP-10 and LP-310.
Lipella remains an SEC reporting company and will continue filing periodic reports.

item 3.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.